Pfizer (PFE) Stock Overview
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
PFE Community Fair Values
Create NarrativeSee what 904 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Pfizer Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$27.00 |
| 52 Week High | US$28.75 |
| 52 Week Low | US$21.97 |
| Beta | 0.39 |
| 1 Month Change | -0.15% |
| 3 Month Change | 1.89% |
| 1 Year Change | 17.14% |
| 3 Year Change | -31.14% |
| 5 Year Change | -32.21% |
| Change since IPO | 5,858.63% |
Recent News & Updates
Recent updates
Pfizer: Painful Recovery Underway
Apr 17Pfizer (NYSE:PFE) Has Announced A Dividend Of $0.43
Jan 08
Pfizer (NYSE:PFE) Has Affirmed Its Dividend Of $0.43
Dec 18Solid Earnings Reflect Pfizer's (NYSE:PFE) Strength As A Business
Aug 12
Pfizer's Q1 Update May Mark A Bottom In The Stock
Apr 30Pfizer Earnings Preview: Pharma May Plumb New Depths After Obesity Drug Debacle
Apr 23Pfizer: Tasty 7% Yield
Apr 16R&D And Savings Programs Will Strengthen Future Outlook
Focus on R&D productivity in 2025 may risk misalignment with market needs, impacting future revenue if new products underperform.Oncology Integration And Phase III Trials Will Redefine Future
Pfizer's oncology focus strengthens its portfolio and future revenue through Seagen integration and promising R&D pipeline developments in oncology and vaccines.Pfizer: Shares Stabilize At $25 As Institutions Begin To Load Up (Rating Upgrade)
Mar 28Shareholder Returns
| PFE | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.9% | -2.9% | 0.3% |
| 1Y | 17.1% | 21.2% | 30.3% |
Return vs Industry: PFE underperformed the US Pharmaceuticals industry which returned 21.2% over the past year.
Return vs Market: PFE underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| PFE volatility | |
|---|---|
| PFE Average Weekly Movement | 3.4% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: PFE has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PFE's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1849 | 75,000 | Albert Bourla | www.pfizer.com |
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19.
Pfizer Inc. Fundamentals Summary
| PFE fundamental statistics | |
|---|---|
| Market cap | US$153.59b |
| Earnings (TTM) | US$7.75b |
| Revenue (TTM) | US$62.58b |
Is PFE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PFE income statement (TTM) | |
|---|---|
| Revenue | US$62.58b |
| Cost of Revenue | US$15.14b |
| Gross Profit | US$47.44b |
| Other Expenses | US$39.69b |
| Earnings | US$7.75b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 05, 2026
| Earnings per share (EPS) | 1.36 |
| Gross Margin | 75.81% |
| Net Profit Margin | 12.38% |
| Debt/Equity Ratio | 74.9% |
How did PFE perform over the long term?
See historical performance and comparisonDividends
Does PFE pay a reliable dividends?
See PFE dividend history and benchmarks| Pfizer dividend dates | |
|---|---|
| Ex Dividend Date | May 08 2026 |
| Dividend Pay Date | Jun 12 2026 |
| Days until Ex dividend | 10 days |
| Days until Dividend pay date | 45 days |
Does PFE pay a reliable dividends?
See PFE dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/27 17:49 |
| End of Day Share Price | 2026/04/24 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pfizer Inc. is covered by 44 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Kerry Holford | Berenberg |